Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ANGELES, CA / ACCESSWIRE / April 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Checkpoint Therapeutics, Inc. ("Checkpoint" or "the Company") (NASDAQ:CKPT) for for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between March 10, 2021 and December 15, 2023, inclusive (the "Class Period"), are encouraged to contact the firm before June 4, 2024.

IMPORTANT DEADLINE NOTICE: The Schall Law Firm Encourages Investors in Checkpoint Therapeutics, Inc. with Losses to Contact the Firm

SAN DIEGO--(BUSINESS WIRE)---- $CKPT #CKPT--Robbins LLP is Investigating the Allegations that Checkpoint Therapeutics, Inc. Overstated the Prospects of its Lead Product Candidate, Cosibelimab.

Checkpoint Therapeutics, Inc. Stockholder Alert: Robbins LLP Reminds Investors of the CKPT Class Action

LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of Checkpoint Therapeutics, Inc. (“Checkpoint” or the “Company”) (NASDAQ: CKPT) on behalf of investors concerning the Company's possible violations of federal securities laws. If you are a shareholder who suffered a loss, click here to participate. On December 18, 2023, Checkpoint disclosed that the U.S. Food and Drug Administration (“FDA”) had not approved the Biologics License Application (“BLA”) that th.

The Law Offices of Frank R. Cruz Announces Investigation of Checkpoint Therapeutics, Inc. (CKPT) on Behalf of Investors

NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Checkpoint Therapeutics, Inc. (NASDAQ: CKPT) between March 10, 2021 and December 15, 2023, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 4, 2024. SO WHAT: If you purchased Checkpoint securities during.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Checkpoint Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – CKPT

NEW YORK , April 5, 2024 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT) and certain officers. The class action, filed in the United States District Court for the Southern District of New York, and docketed under 24-cv-02613, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Checkpoint securities between March 10, 2021 and December 15, 2023, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Checkpoint Therapeutics, Inc. and Certain Officers - CKPT

Fortress Biotech

WALTHAM, Mass., March 22, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2023, and recent corporate highlights.

Checkpoint Therapeutics Reports Full-Year 2023 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., March 18, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the appointment of Amit Sharma, M.D., FACP, FASN, FNKF, to its Board as an independent, non-executive director, effective immediately.

Checkpoint Therapeutics Announces Appointment of Accomplished Life Sciences Executive Amit Sharma, M.D. to Board of Directors

WALTHAM, Mass., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement with a single healthcare-dedicated institutional investor for the issuance and sale of an aggregate of 7,756,233 shares of its common stock (or common stock equivalents in lieu thereof) at a purchase price of $1.805 per share of common stock (or per common stock equivalent in lieu thereof), in a registered direct offering priced at-the-market. In addition, in a concurrent private placement, Checkpoint will issue and sell unregistered warrants to purchase up to 7,756,233 shares of common stock. The warrants will have an exercise price of $1.68 per share, will be exercisable immediately upon issuance and will expire five years following the issuance date.

Checkpoint Therapeutics Announces $14 Million Registered Direct Offering Priced At-the-Market

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:00 p.m. EST.

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

NEW YORK , Jan. 6, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Checkpoint Therapeutics, Inc. - CKPT

NEW YORK , Dec. 19, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of Checkpoint Therapeutics, Inc. ("Checkpoint" or the "Company") (NASDAQ: CKPT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Checkpoint Therapeutics, Inc. - CKPT

Checkpoint Therapeutics (NASDAQ:CKPT) Inc shares plummeted 48% to $1.72 in midday trading on Monday after the US Food and Drug Administration (FDA) failed to approve its drug development candidate Cosibelimab, the clinical-stage immunotherapy and targeted oncology company's experimental therapy to treat a type of advanced skin cancer.  In its complete response letter (CRL), the FDA cited issues related to a third-party contract manufacturer as the reason for its decision.

Checkpoint Therapeutics stock plunges on FDA setback

Checkpoint Therapeutics said on Monday the U.S. Food and Drug Administration had declined to approve its experimental therapy to treat a form of skin cancer following an inspection at a contract manufacturer, sending its shares down nearly 50%.

Checkpoint Therapeutics slides after US FDA declines cancer therapy approval

FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab FDA did not state any concerns about the clinical data package, safety, or labeling for the approvability of cosibelimab

U.S. Food and Drug Administration Issues Complete Response Letter for Cosibelimab Solely Due to Inspection Findings at Third-Party Manufacturer

Anixa Biosciences Inc

Structure Therapeutics Inc

Some of the most explosive opportunities can be found in biotech stocks.  Look at CRISPR Therapeutics (NASDAQ: CRSP ), for example.

3 Biotech Stocks to Turn $5,000 Into $1 Million: December 2023

Aclaris Therapeutics

G1 Therapeutics

2Seventy Bio

Penny stocks, securities with share prices under $5, offer investors a chance at exponential returns with little upfront investment. However, investing wisely in penny stocks requires research as their prices fluctuate wildly around key events.

Best Penny Stocks To Buy? 4 To Watch With Big News This Week

Upcoming PDUFA goal date of January 3, 2024 U.S. patent protection for cosibelimab through at least May 2038 WALTHAM, Mass., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Patent and Trademark Office (“USPTO”) has issued a new patent (U.S. Patent No.

Checkpoint Therapeutics Strengthens Intellectual Property Protection for Cosibelimab with New U.S. Patent Issuance

Biologics License Application for cosibelimab under review by U.S. FDA; PDUFA goal date of January 3, 2024 Recent publication of cosibelimab pivotal trial results in the Journal for ImmunoTherapy of Cancer WALTHAM, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2023, and recent corporate highlights.

Checkpoint Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights

Cosibelimab is the first PD-L1–blocking antibody to demonstrate a robust, durable and clinically meaningful objective response, and a manageable safety profile, in patients with metastatic cutaneous squamous cell carcinoma

Checkpoint Therapeutics Announces Publication of Cosibelimab Pivotal Trial Results in the Journal for ImmunoTherapy of Cancer

WALTHAM, Mass., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding (i) Series A warrants to purchase up to an aggregate of 1,734,105 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,734,105 shares of common stock, each having an exercise price of $4.075 per share, issued by Checkpoint on December 16, 2022 and (ii) Series A warrants to purchase up to an aggregate of 1,428,572 shares of common stock and Series B Series warrants to purchase up to an aggregate of 1,428,572 shares of common stock issued by Checkpoint on February 22, 2023, each having an exercise price of $5.00 per share, at a reduced exercise price of $1.76 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File No. 333-251005) and Form S-3 (File No. 333-270474), respectively. The gross proceeds to Checkpoint from the exercise of the warrants are expected to be approximately $11.13 million, prior to deducting placement agent fees and estimated offering expenses. The closing of the offering is expected to occur on or about October 4, 2023, subject to satisfaction of customary closing conditions.

Checkpoint Therapeutics Announces Exercise of Warrants for $11.13 Million in Gross Proceeds

WALTHAM, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a panel presentation at the Cantor Global Healthcare Conference on Thursday, September 28, 2023, at 10:20 a.m. ET in New York City. The Company will also attend in-person one-on-one meetings during the conference.

Checkpoint Therapeutics to Participate in the Cantor Global Healthcare Conference

WALTHAM, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference on Monday, September 11, 2023, at 2:30 p.m. ET. The Company will also attend in-person and virtual one-on-one meetings during the conference.

Checkpoint Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference

Biologics License Application for cosibelimab under review by U.S. FDA; Successful mid-cycle meeting with U.S. FDA completed; PDUFA goal date of January 3, 2024

Checkpoint Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

A PDUFA date of January 3, 2024 has been established by which FDA will decide upon by then whether or not cosibelimab should be approved for the treatment of cSCC. It is said that the cutaneous squamous cell carcinoma market in the U.S. alone could reach $1.6 billion. Company plans to compete with other PD-1/PD-L1 inhibitors in terms of mechanism of action, which gives cosibelimab an improved safety profile over other drugs in the same class.

Checkpoint: PDUFA Date Catalyst Makes This A Must Watch

WALTHAM, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 3,236,248 shares of its common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to 3,236,248 shares of common stock and Series B warrants to purchase up to 3,236,248 shares of common stock, at a purchase price of $3.09 per share of common stock (or pre-funded warrant in lieu thereof) and associated warrants, in a registered direct offering priced at-the-market.

News for Checkpoint Therapeutics Stock (CKPT)